top of page
  • Amazon
  • Youtube
  • TikTok
  • Facebook
  • Instagram
Copy of kindle cover.jpg

WE'RE RELYING ON YOU TO SUPPORT OTP

​​AT ZERO COST TO YOU:

Subscribe to our YouTube channel – It’s completely free, and we’re pushing toward 100,000 subscribers to amplify this movement. Your sub helps keep this work alive and growing.

​

​

​


​

​

​

A FEW DOLLARS GETS YOU A BOOK, AND AMPLIFIES OUR MESSAGE

Pick up our book! At just $12.99 for a paperback or $7.99 on Kindle, your support keeps us on the Amazon bestseller charts, proving that this information is too important to ignore.

​

​

Search

Higher Doses of Zepbound and Mounjaro Being Tested

As we continually seek more effective strategies in managing type 2 diabetes and obesity, emerging research into higher doses of tirzepatide presents promising new options, particularly for those who have seen limited results from current dosages. The latest study delves into the potential of 2 investigational higher doses— 20mg and 25mg according to our sources.



The clinical trial, officially referenced as NCT06037252, is rigorously designed to evaluate the safety and efficacy of tirzepatide in doses previously unexplored. This investigation focuses specifically on whether increased doses can provide enhanced benefits that many patients desperately need.


For patients categorized as “slower responders” to the existing maximum dose of 15mg, these investigational doses may offer the breakthrough needed. By intensifying the treatment, there is potential not only to enhance glucose control but also to accelerate weight loss outcomes—key factors in managing type 2 diabetes and associated obesity.


This ongoing study could mark a significant advancement in treatment options, providing new hope and potentially more robust solutions for individuals whose needs surpass the current offerings. Trial NCT06037252 officially commenced on September 21, 2023, with the primary endpoints of the study expected to be reached by December 24, 2024. Preliminary results will soon shed light on the efficacy and safety of the higher doses. The entire study is anticipated to wrap up by September 30, 2025, providing comprehensive data that could potentially reshape current treatment paradigms for those who have had limited success with existing therapies.



WE RELY ON YOUR GENEROSITY FOR THE WORK WE DO, CONSIDER A GIFT THROUGH CASH APP OR VENMO TO SUPPORT OUR CONTINUED AND TIRELESS EFFORTS!


 
 
 
bottom of page